WHO Grade III Glioma Clinical Trials

8 recruiting

WHO Grade III Glioma Trials at a Glance

9 actively recruiting trials for who grade iii glioma are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Houston, Columbus, and Boston. Lead sponsors running who grade iii glioma studies include Nationwide Children's Hospital, M.D. Anderson Cancer Center, and Beijing Tiantan Hospital.

Browse who grade iii glioma trials by phase

Treatments under study

About WHO Grade III Glioma Clinical Trials

Looking for clinical trials for WHO Grade III Glioma? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new WHO Grade III Glioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about WHO Grade III Glioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

WHO Grade III GliomaWHO Grade II GliomaRecurrent WHO Grade III Glioma+1 more
Susan Chang300 enrolled1 locationNCT04540107
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Early Phase 1

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Not Applicable

Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

GlioblastomaWHO Grade III GliomaWHO Grade II Glioma
M.D. Anderson Cancer Center117 enrolled1 locationNCT04479696
Recruiting
Phase 2

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

GlioblastomaOligodendrogliomaWHO Grade III Glioma+6 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04623931
Recruiting
Phase 2

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Recurrent Diffuse Intrinsic Pontine GliomaDiffuse Intrinsic Pontine GliomaWHO Grade III Glioma+3 more
University of California, San Francisco360 enrolled32 locationsNCT05009992
Recruiting
Phase 2

Study of Olutasidenib and Temozolomide in HGG

Metastatic Brain TumorIDH1 MutationAstrocytoma, Grade IV+16 more
Rigel Pharmaceuticals60 enrolled18 locationsNCT06161974
Recruiting
Phase 1

Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas

WHO Grade III GliomasWHO Grade IV Gliomas
Beijing Tiantan Hospital12 enrolled1 locationNCT06253234